Regeneron Gains After Eye-Drug Patent Victory Over Viatris (1)

Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc.

The Viatris copy violates a Regeneron patent on its Eylea medication, according to the ruling Wednesday from the US District Court for the Northern District of West Virginia. Regeneron shares closed up 2.9%, their biggest gain since Nov. 2. Viatris shares rose less than 1%.

Regeneron sued Viatris’ Mylan unit in August 2022, alleging that its proposed biosimilar copy of Eylea infringed 24 patents for the ...